March 8, 2019
Sedana Medical’s study of IsoConDa for inhalation sedation needs less patients than expected
Sedana Medical phase III study of candidate drug IsoConDa (isoflurane) for inhalation sedation in intensive care in Europe, shows smaller variations in efficacy than anticipated and the study will therefore only need to cover a total of 300 patients instead of initially estimated 550 patients.